Clinical advantages of dual activity in urticaria
- 1 December 2000
- Vol. 55 (s64), 28-33
- https://doi.org/10.1034/j.1398-9995.2000.00804.x
Abstract
Urticaria is a common disorder that adversely affects quality of life; work-related and recreational activities are restricted, while rest, sleep, and emotions are seriously disturbed in a significant proportion of patients. The pathogenic mechanisms vary, but cutaneous mast-cell activation with release of histamine and other vasoactive or proinflammatory mediators is thought to be the final common pathway for lesion induction in most cases. A subsequent, but incompletely understood, late-phase allergic reaction seems to prolong the inflammatory process, particularly in certain chronic forms of the disorder. Although histamine is considered an important mediator of urticaria, additional substances, including the cysteinyl leukotrienes (LTs), are putative mediators of the immediate urticarial responses and the inflammatory events that follow in some types of urticaria. A second-generation antihistamine, mizolastine, which exhibits dual activity with selective H1-receptor antagonism and, as shown in animal studies, anti-5-lipoxygenase activity, represents an advance in the treatment of urticaria. It has rapid, potent and sustained action. At the recommended 10-mg dose, mizolastine suppresses the histamine-induced wheal reaction as early as 1 h after oral administration. Compared to placebo, mizolastine significantly reduces overall patient discomfort and pruritus in patients with chronic idiopathic urticaria. Double-blind, placebo-controlled studies have also shown mizolastine to be at least as effective as other second-generation antihistamines. Furthermore, with long-term use of mizolastine over 1 year, a reduction in pruritus and the number of urticarial episodes was maintained with no evidence of tachyphylaxis or tolerance. Mizolastine has also been shown to be an effective treatment for cold-induced urticaria, causing significant delay in the whealing response to the ice-cube test and also reducing the wheal diameter.Keywords
This publication has 8 references indexed in Scilit:
- One-year treatment of chronic urticaria with mizolastine: efficacy and safetyJournal of the European Academy of Dermatology and Venereology, 2000
- Antihistamines in urticariaClinical and Experimental Allergy, 1999
- Efficacy and safety of mizolastine 10 mg in a placebo‐controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR study1Journal of the European Academy of Dermatology and Venereology, 1999
- Microvascular actions of histamine: synergism with leukotriene B4 and role in allergic leucocyte recruitmentClinical and Experimental Allergy, 1997
- The impact of chronic urticaria on the quality of lifeBritish Journal of Dermatology, 1997
- Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticariaAllergy, 1996
- Urticaria and angioedemaJournal of Allergy and Clinical Immunology, 1983
- URTICARIA AND ANGIO-OEDEMA.British Journal of Dermatology, 1969